[Perspectives for the treatment and prevention of herpes simplex infections].
Rega Institute for Medical Research, Katholieke Universiteit Leuven - Leuven (Belgique).
R
R
Snoeck
D015075:2-Aminopurine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000212:Acyclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000634:Aminoquinolines / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D000077404:Cidofovir; D003596:Cytosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D000077595:Famciclovir; D006561:Herpes Simplex / Q000188:drug therapy* / Q000517:prevention & control; D022301:Herpes Simplex Virus Vaccines / Q000627:therapeutic use; D018259:Herpesvirus 1, Human; D018258:Herpesvirus 2, Human; D006801:Humans; D000077271:Imiquimod; D007369:Interferon Inducers / Q000627:therapeutic use; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000634:Aminoquinolines; D000998:Antiviral Agents; D022301:Herpes Simplex Virus Vaccines; D007369:Interferon Inducers; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D015075:2-Aminopurine; D003596:Cytosine; D014633:Valine; D000077404:Cidofovir; D000077483:Valacyclovir; D000077271:Imiquimod; D000077595:Famciclovir; D000212:Acyclovir